Form D · Other Health Care
CollPlant Biotechnologies Ltd
Rehovot, L3 · CIK 0001631487
Offering snapshot reported Oct 22, 2026 · SEC filing
- Reported sold
- $9.25M Offering amount: $9.25M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 9, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 22, 2026 | Initial | $9,249,958 | No comparison | 5 | SEC filing |
| Jul 20, 2026 | Initial | $10,400,000 | No comparison | 5 | SEC filing |
| Feb 17, 2026 | Initial | $4,000,000 | No comparison | 8 | SEC filing |
| Jun 4, 2025 | Initial | $3,870,006 | No comparison | 4 | SEC filing |
| Mar 9, 2020 | Initial | $4,450,000 | No comparison | 14 | SEC filing |
| Sep 10, 2019 | Initial | $3,500,000 | No comparison | 8 | SEC filing |
| Nov 3, 2017 | Initial | $2,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $224K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-602262
Including the exercise price of ordinary shares underlying such warrants at an exercise price of $3.74. The total offering amount excludes placement agent warrants (see Item 15).
ordinary warrants to purchase ordinary shares, including underlying ordinary shares upon exercise.
Sales Commission includes cash placement fee. Other comp. included management fee, a $35,000 expense allowance, reimbursement of $50,000 for legal fees, $15,950 in clearing fees, and 59,358 warrants with an ex. price of $4.675/share.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 000000375 | |
| Rodman & Renshaw, LLC | 000281264 |
Source: Form D, filed Oct 22, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Bar Abelis | Executive |
| Bowman Bagley | Executive |
| Ilana Belzer | Executive |
| Ruti Ben Shlomi | Director, Executive |
| Philippe Bensimon | Executive |
| Scott Burrell | Director |
| Hugh Evans | Director |
| Oren Fahimipoor | Executive |
| Elana Gazal | Executive |
| Adi Goldin | Director |
| Gili Hart | Director |
| Abraham Havron | Director |
| Hadas Dreiher Horowitz | Executive |
| Alisa Lask | Director |
| Nadav Orr | Executive |
| Elan Penn | Director |
| Roger Dreiher Pomerantz | Director |
| Eran Rotem | Executive |
| Wolfgang Ruttenstorfer | Director |
| Jasmine Seror | Executive |
| Oded Shoseyov | Executive |
| Shomrat Shurtz | Executive |
| Yehiel Tal | Director, Executive |
| David Tsur | Director |
| Joseph Zarzewsky | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
4 Oppenheimer, Weizmann Science Park
Rehovot, L3, 7670104
Rehovot, L3, 7670104